Fund Details
Finchley Healthcare Ventures
Overview
Investment portfolio
4rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Coultreon Biopharma | Apr 2026Participated | $125 MSeries A | |
Triana Biomedicines | Dec 2025Participated | $120 MSeries B | |
Cartography Biosciences | Oct 2025Participated | $67 MSeries B | |
Reverb Therapeutics | Feb 2025Participated | $12 MSeed | |
Coultreon Biopharma | Apr 2026Participated | $125 MSeries A | |
Triana Biomedicines | Dec 2025Participated | $120 MSeries B | |
Cartography Biosciences | Oct 2025Participated | $67 MSeries B | |
Reverb Therapeutics | Feb 2025Participated | $12 MSeed |
4 Items
4
Items
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 1 |
| Series A | 0 | 1 |
| Series B | 0 | 2 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Feb '25 | 1 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 1 |
| Nov '25 | 0 |
| Dec '25 | 1 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 1 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 4 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 1 |
| $25M-$50M | 0 |
| $50M-$100M | 1 |
| $100M-$250M | 2 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 2 |
| Canada | 1 |
| Europe | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Pfizer Ventures | 2 |
| Regeneron Ventures | 2 |
| 8VC | 1 |
| AME Cloud Ventures | 1 |
| Amgen Ventures | 1 |
| Amplitude Ventures | 1 |
| Andreessen Horowitz | 1 |
| ARTIS Ventures | 1 |
| Ascenta Capital | 1 |
| Atlas Venture | 1 |
| Balyasny Asset Management | 1 |
| Bessemer Venture Partners | 1 |
| Catalio Capital Management | 1 |
| Forbion | 1 |
| Gaingels | 1 |
| Galapagos | 1 |
| Global BioAccess Fund | 1 |
| InBC Investment | 1 |
| Invus | 1 |
| KdT Ventures | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 0 | 0% |
| Participating | 4 | 100% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 0 | 0% |
Lead dynamics requires at least one led deal in this range
Team
David Goodman
Founder